More on BHVN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+62.8% Growth)
- Ratings (6.4 Score)
- Holders
- Event Driven Deals

Upcoming Events

- Earnings (11/17/26)
- M&A (3/31/23 *Est)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Biohaven Pharma (NY:BHVN)
Delayed: 15.11 -0.58 (3.7%)
Prev. Close $15.69  
Open$14.91 
52 Wk High$ 
52 Wk Low$ 
Day High$15.80 
Day Low$14.33 
P/E N/A  
EPS$ 
Volume1,115,109 

Friends, Peers and Foes (?): QURE, ALKS, AMGN, AXSM, CGON (more...)

Sep 8, 2026 02:19 AM RBC Capital Downgrades Biohaven Pharma (BHVN) to Sector Perform
Aug 28, 2026 08:10 AM Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)
Aug 27, 2026 07:07 AM H.C. Wainwright Reiterates Neutral Rating on Biohaven Pharma (BHVN)
Aug 26, 2026 11:01 AM TD Cowen Reiterates Buy Rating on Biohaven Pharma (BHVN)
Aug 26, 2026 10:17 AM Biohaven Pharma (BHVN) PT Lowered to $30 at Raymond James
Aug 26, 2026 07:05 AM Biohaven licenses Kv7 epilepsy platform to SK Biopharma for up to $795M
Aug 26, 2026 06:39 AM Form 8-K Biohaven Ltd. For: Aug 26
Aug 26, 2026 02:37 AM Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Aug 25, 2026 04:44 PM Court awards Biohaven and Yale $4M in trade secret case
Aug 25, 2026 04:42 PM Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale
View All Articles

Entities mentioned with BHVN

View All Entities